OncoMatch/Clinical Trials/NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Is NCT05592626 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies STAR0602 for advanced solid tumors.
Treatment: STAR0602 — This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Allowed: KRAS wild-type
CRC (both Ras wild type and mutant)
Allowed: KRAS mutation
CRC (both Ras wild type and mutant)
Disease stage
Required: Stage III, IV, PRIMARY STAGE IV
unresectable, locally advanced, or metastatic
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Loma Linda University Cancer Center · Loma Linda, California
- UC Davis Comprehensive Cancer Center · Sacramento, California
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- AdventHealth Celebration · Celebration, Florida
- University of Miami Sylvester Comprehensive Cancer Center · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify